Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | FABP7 | O15540 | 3/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.49 |
| ▸ | FABP3 | P05413 | 1/20 | 0.48 |
| ▸ | P4HB | P07237 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16869915 | 0.88 | POLB (1.00) | POLBALDH1A1TSHRATMPPARG | |
| SCHEMBL16870078 | 0.88 | POLB (1.00) | POLBALDH1A1TSHRATMPPARG | |
| SCHEMBL16869924 | 0.88 | POLB (1.00) | POLBALDH1A1TSHRATMPPARG | |
| SCHEMBL16866274 | 0.88 | POLB (1.00) | POLBALDH1A1TSHRATMPPARG | |
| SCHEMBL14225120 | 0.86 | POLB (0.89) | POLBALDH1A1TSHRATMPPARG | |
| SCHEMBL8067771 | 0.86 | POLB (0.82) | POLBALDH1A1TSHRATMPPARG | |
| SCHEMBL8067775 | 0.86 | POLB (0.82) | POLBALDH1A1TSHRATMPPARG | |
| SCHEMBL19355164 | 0.86 | POLB (0.89) | POLBALDH1A1TSHRATMPPARG | |
| SCHEMBL18674039 | 0.83 | POLB (0.54) | POLBALDH1A1PPARGHTTGAA | |
| SCHEMBL19355100 | 0.80 | FABP7 (0.78) | POLBALDH1A1TSHRPPARGHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216241-A1 | ALPHA- AND GAMMA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216241-A1 | ALPHA- AND GAMMA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | FABP1, FABP2, FABP7 | POLB 4667/4885ALDH1A1 1091/4885TSHR 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.